Epsilogen Ltd.

Epsilogen Completes Series B Expansion to Advance IgE Antibody Therapy for Ovarian Cancer

- Epsilogen secured additional funding of £12.5m in Series B expansion, bringing the total to £43.25m, to support clinical development of its IgE antibody pipeline. - The lead candidate, MOv18 IgE, will be evaluated in a Phase Ib trial for platinum-resistant ovarian cancer, showing promise as a first-in-class cancer IgE antibody. - MOv18 IgE targets folate receptor alpha, which is overexpressed in various cancers, and has demonstrated safety and initial clinical activity in a Phase I trial. - Epsilogen is also advancing its IgE-based pipeline, including IgE bispecifics and IgE/IgG combination antibody molecules, to enhance functionality in oncology.